Previous 10 | Next 10 |
home / stock / teva / teva articles
Teva Pharmaceutical Indus (NYSE:TEVA) has outperformed the market over the past 5 years by 3.91% on an annualized basis producing an average annual...
The Federal Trade Commission (FTC) has initiated an investigation into Teva Pharmaceutical Industries Ltd (NYSE:TEVA) over its refusal to remove ab...
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is reportedly in active discussions to settle a lawsuit with the U.S. Department of Justice (DOJ). T...
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA)...
These large-cap stocks were the best performers in the last week. Are they in your portfolio? Teva Pharmaceutical Industries (NYSE:TEVA) shares s...
Wednesday, Teva Pharmaceutical Industries Ltd (NYSE:TEVA) and Medincell announced results from the efficacy portion of the Phase 3 SOLARI...
Shares of Upstart Holdings, Inc. (NASDAQ:UPST) fell sharply during Wednesday's session after the company reported first-quarter financial resu...
U.S. stocks were mixed, with the Dow Jones gaining around 70 points on Wednesday. Shares of Louisiana-Pacific Corporation (NYSE:LPX) rose sharply d...
U.S. stocks are on track for a mixed start on Wednesday as the market digests mixed earnings reports and looks ahead to more speeches by Federal Re...
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
Teva Pharmaceutical Industries Limited American Depositary Shares Website:
2024-07-10 08:00:08 ET Ashwani Verma from UBS issued a price target of $24.00 for TEVA on 2024-07-10 07:20:00. The adjusted price target was set to $24.00. At the time of the announcement, TEVA was trading at $15.81. The overall price target consensus is at $15.00 with h...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8...
4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) congress in Helsinki New sub-analysis of PEARL data highlights potential negative impact of treatment pauses on patient outcomes 1 Sub-analysis explorin...